File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Clinical characteristics, risk factors and outcomes of cancer patients with COVID-19: A population-based study

TitleClinical characteristics, risk factors and outcomes of cancer patients with COVID-19: A population-based study
Authors
Keywordscancer
COVID-19
intensive care unit
intubation
mortality
Issue Date2023
Citation
Cancer Medicine, 2023, v. 12, n. 1, p. 287-296 How to Cite?
AbstractIntroduction: Cancer patients may be susceptible to poorer outcomes in COVID-19 infection owing to the immunosuppressant effect of chemotherapy/radiotherapy and cancer growth, along with the potential for nosocomial transmission due to frequent hospital admissions. Methods: This was a population-based retrospective cohort study of COVID-19 patients who presented to Hong Kong public hospitals between 1 January 2020 and 8 December 2020. The primary outcome was a composite endpoint of requirement for intubation, ICU admission and 30-day mortality. Results: The following study consisted of 6089 COVID-19 patients (median age 45.9 [27.8.1–62.7] years; 50% male), of which 142 were cancer subjects. COVID-19 cancer patients were older at baseline and tended to present with a higher frequency of comorbidities, including diabetes mellitus, hypertension, chronic obstructive pulmonary disease, ischemic heart disease, ventricular tachycardia/fibrillation and gastrointestinal bleeding (p < 0.05). These subjects also likewise tended to present with higher serum levels of inflammatory markers, including D-dimer, lactate dehydrogenase, high sensitivity troponin-I and C-reactive protein. Multivariate Cox regression showed that any type of cancer presented with an almost four-fold increased risk of the primary outcome (HR: 3.77; 95% CI: 1.63–8.72; p < 0.002) after adjusting for significant demographics, Charlson comorbidity index, number of comorbidities, past comorbidities and medication history. This association remained significant when assessing those with colorectal (HR: 5.07; 95% CI: 1.50–17.17; p < 0.009) and gastrointestinal malignancies (HR: 3.79; 95% CI: 1.12–12.88; p < 0.03), but not with lung, genitourinary, or breast malignancies, relative to their respective cancer-free COVID-19 counterparts. Conclusions: COVID-19 cancer patients are associated with a significantly higher risk of intubation, ICU admission and/or mortality.
Persistent Identifierhttp://hdl.handle.net/10722/330806

 

DC FieldValueLanguage
dc.contributor.authorZhou, Jiandong-
dc.contributor.authorLakhani, Ishan-
dc.contributor.authorChou, Oscar-
dc.contributor.authorLeung, Keith Sai Kit-
dc.contributor.authorLee, Teddy Tai Loy-
dc.contributor.authorWong, Michelle Vangi-
dc.contributor.authorLi, Zhen-
dc.contributor.authorWai, Abraham Ka Chung-
dc.contributor.authorChang, Carlin-
dc.contributor.authorWong, Ian Chi Kei-
dc.contributor.authorZhang, Qingpeng-
dc.contributor.authorTse, Gary-
dc.contributor.authorCheung, Bernard Man Yung-
dc.date.accessioned2023-09-05T12:14:36Z-
dc.date.available2023-09-05T12:14:36Z-
dc.date.issued2023-
dc.identifier.citationCancer Medicine, 2023, v. 12, n. 1, p. 287-296-
dc.identifier.urihttp://hdl.handle.net/10722/330806-
dc.description.abstractIntroduction: Cancer patients may be susceptible to poorer outcomes in COVID-19 infection owing to the immunosuppressant effect of chemotherapy/radiotherapy and cancer growth, along with the potential for nosocomial transmission due to frequent hospital admissions. Methods: This was a population-based retrospective cohort study of COVID-19 patients who presented to Hong Kong public hospitals between 1 January 2020 and 8 December 2020. The primary outcome was a composite endpoint of requirement for intubation, ICU admission and 30-day mortality. Results: The following study consisted of 6089 COVID-19 patients (median age 45.9 [27.8.1–62.7] years; 50% male), of which 142 were cancer subjects. COVID-19 cancer patients were older at baseline and tended to present with a higher frequency of comorbidities, including diabetes mellitus, hypertension, chronic obstructive pulmonary disease, ischemic heart disease, ventricular tachycardia/fibrillation and gastrointestinal bleeding (p < 0.05). These subjects also likewise tended to present with higher serum levels of inflammatory markers, including D-dimer, lactate dehydrogenase, high sensitivity troponin-I and C-reactive protein. Multivariate Cox regression showed that any type of cancer presented with an almost four-fold increased risk of the primary outcome (HR: 3.77; 95% CI: 1.63–8.72; p < 0.002) after adjusting for significant demographics, Charlson comorbidity index, number of comorbidities, past comorbidities and medication history. This association remained significant when assessing those with colorectal (HR: 5.07; 95% CI: 1.50–17.17; p < 0.009) and gastrointestinal malignancies (HR: 3.79; 95% CI: 1.12–12.88; p < 0.03), but not with lung, genitourinary, or breast malignancies, relative to their respective cancer-free COVID-19 counterparts. Conclusions: COVID-19 cancer patients are associated with a significantly higher risk of intubation, ICU admission and/or mortality.-
dc.languageeng-
dc.relation.ispartofCancer Medicine-
dc.subjectcancer-
dc.subjectCOVID-19-
dc.subjectintensive care unit-
dc.subjectintubation-
dc.subjectmortality-
dc.titleClinical characteristics, risk factors and outcomes of cancer patients with COVID-19: A population-based study-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1002/cam4.4888-
dc.identifier.pmid35642123-
dc.identifier.scopuseid_2-s2.0-85131016004-
dc.identifier.volume12-
dc.identifier.issue1-
dc.identifier.spage287-
dc.identifier.epage296-
dc.identifier.eissn2045-7634-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats